|Budget Amount *help
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
In a retrospective study of 101 patients infected with either genotype 2a (n = 65) or 2b (n = 36) and treated with peginterferon plus ribavirin, we investigated predictive factors for a sustained virological response (SVR), including genetic variations near the IL28B gene and clinical variables such as age, gender, body mass index, stage of fibrosis, and drug adherence. Ultra-rapid virological response, rapid virological response (RVR), end-of-treatment response, SVR, and relapse rates were 22.2%, 61.4%, 95.0%, 87.1%, and 7.9%, respectively. In univariate analysis, RVR and IL28B single-nucleotide polymorphisms (SNPs) were significantly associated with SVR. In subgroup analysis, IL28B SNPs were significantly associated with SVR in genotype 2a patients but not in genotype 2b patients. In multiple logistic regression analysis, RVR and IL28B SNP (rs8099917) were independently associated with SVR. Furthermore, IL28B SNP was significantly associated with relapse but RVR was not.